Another meta-analysis hath disclosed that, in comparison to patients with EGFR mutations, those afflicted with EGFR wild-type NSCLC evince significantly protracted progression-free survival (P < 0.00001) and OS (P < 0.05) after immunotherapy with programmed cell death protein 1 (PD-1)/PD-L1 inhibitors (37). This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.